Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise. Shortly after the turn of the century, Gilead Sciences took a ...

Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical industry. Financial performance highlights potential challenges and growth opportunities for ...

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab, the centre piece of its $4.9 billion acquisition of Forty Seven in 2020.

Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir at the HIV Glasgow medical meeting. The data from the ...

Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court ...

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ...